R. Laxminarayan, A. Duse, C. Wattal, A. Zaidi, H. Wertheim et al., Antibiotic resistance???the need for global solutions, The Lancet Infectious Diseases, vol.13, issue.12, pp.1057-1098
DOI : 10.1016/S1473-3099(13)70318-9

G. Wright and H. Poinar, Antibiotic resistance is ancient: implications for drug discovery, Trends in Microbiology, vol.20, issue.4, pp.157-159, 2012.
DOI : 10.1016/j.tim.2012.01.002

H. Grundmann, K. Klugman, T. Walsh, P. Ramon-pardo, B. Sigauque et al., A framework for global surveillance of antibiotic resistance, Drug Resistance Updates, vol.14, issue.2, pp.79-87, 2011.
DOI : 10.1016/j.drup.2011.02.007

E. Valade, A. Davin-regli, J. Bolla, and J. Pagès, Bacterial membrane, a key for controlling influx and efflux, p 217240 Antibiotics, targets, mechanisms and resistance, 2013.
DOI : 10.1002/9783527659685.ch9
URL : http://doi.org/10.1002/9783527659685.ch9

A. Davin-regli, J. Bolla, C. James, J. Lavigne, C. J. Garnotel et al., Membrane Permeability and Regulation of Drug “Influx and Efflux” in Enterobacterial Pathogens, Current Drug Targets, vol.9, issue.9, pp.750-759, 2008.
DOI : 10.2174/138945008785747824

J. Pagès, C. James, and M. Winterhalter, The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria, Nature Reviews Microbiology, vol.390, issue.12, pp.893-903, 2008.
DOI : 10.1016/S0969-2126(99)80055-0

H. Nikaido and J. Pagès, Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria, FEMS Microbiology Reviews, vol.36, issue.2, pp.340-363, 2012.
DOI : 10.1111/j.1574-6976.2011.00290.x

S. Drawz, K. Papp-wallace, and R. Bonomo, New ??-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World, Antimicrobial Agents and Chemotherapy, vol.58, issue.4, pp.1835-184600826, 2013.
DOI : 10.1128/AAC.00826-13

G. Zhanel, C. Lawson, H. Adam, F. Schweizer, S. Zelenitsky et al., Ceftazidime-Avibactam: a Novel Cephalosporin/??-lactamase Inhibitor Combination, Drugs, vol.18, issue.Suppl. 3, pp.159-177, 2013.
DOI : 10.1007/s40265-013-0013-7

T. Farmer, B. Degnan, and D. Payne, Penetration of ??-lactamase inhibitors into the periplasm of Gram-negative bacteria, FEMS Microbiology Letters, vol.176, issue.1, pp.11-15, 1999.
DOI : 10.1016/S0378-1097(99)00210-4

H. Nikaido, Molecular Basis of Bacterial Outer Membrane Permeability Revisited, Microbiology and Molecular Biology Reviews, vol.67, issue.4, pp.593-656, 2003.
DOI : 10.1128/MMBR.67.4.593-656.2003

H. Nikaido, E. Rosenberg, and J. Foulds, Porin channels in Escherichia coli: studies with beta-lactams in intact cells, J Bacteriol, vol.153, pp.232-240, 1983.

X. Li, P. Plésiat, and H. Nikaido, The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria, Clinical Microbiology Reviews, vol.28, issue.2, pp.337-41800117, 2015.
DOI : 10.1128/CMR.00117-14

J. Bolla, S. Alibert-franco, J. Handzlik, C. J. Mahamoud, A. Boyer et al., Strategies for bypassing the membrane barrier in multidrug resistant Gram-negative bacteria, FEBS Letters, vol.77, issue.11, pp.1682-1690, 2011.
DOI : 10.1016/j.febslet.2011.04.054
URL : https://hal.archives-ouvertes.fr/hal-01425039

K. Coleman, Diazabicyclooctanes (DBOs): a potent new class of non-??-lactam ??-lactamase inhibitors, Current Opinion in Microbiology, vol.14, issue.5, pp.550-555, 2011.
DOI : 10.1016/j.mib.2011.07.026

D. Ehmann, . Jahic´hjahic´jahic´h, P. Ross, R. Gu, J. Hu et al., Avibactam is a covalent, reversible, non-??-lactam ??-lactamase inhibitor, Proceedings of the National Academy of Sciences, vol.109, issue.29, pp.11663-11668, 2012.
DOI : 10.1073/pnas.1205073109
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406822

D. Ehmann, H. Jahic, P. Ross, R. Gu, J. Hu et al., Kinetics of Avibactam Inhibition against Class A, C, and D ??-Lactamases, Journal of Biological Chemistry, vol.288, issue.39, pp.27960-27971, 2013.
DOI : 10.1074/jbc.M113.485979

T. Stachyra, P. Levasseur, M. Pechereau, A. Girard, M. Claudon et al., In vitro activity of the ??-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases, Journal of Antimicrobial Chemotherapy, vol.64, issue.2, pp.326-329, 2009.
DOI : 10.1093/jac/dkp197

P. Lagacé-wiens, F. Tailor, P. Simner, M. Decorby, J. Karlowsky et al., Activity of NXL104 in combination with -lactams against genetically characterized Escherichia coli Ceftazidime, Avibactam, and Bacterial Porins, 2011.

D. Wiskirchen, J. Crandon, G. Furtado, G. Williams, and D. Nicolau, In Vivo Efficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-??-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae, Antimicrobial Agents and Chemotherapy, vol.55, issue.7, pp.3220-320500024, 2011.
DOI : 10.1128/AAC.00024-11

A. Louie, M. Castanheira, W. Liu, C. Grasso, R. Jones et al., Pharmacodynamics of ??-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of ??-Lactamases, Antimicrobial Agents and Chemotherapy, vol.56, issue.1, pp.258-27005005, 2012.
DOI : 10.1128/AAC.05005-11

D. Livermore, S. Mushtaq, M. Warner, J. Zhang, S. Maharjan et al., Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae, Antimicrobial Agents and Chemotherapy, vol.55, issue.1, pp.390-394, 2011.
DOI : 10.1128/AAC.00756-10

D. Livermore, S. Mushtaq, K. Barker, R. Hope, M. Warner et al., Characterization of ??-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104), Journal of Antimicrobial Chemotherapy, vol.67, issue.6, pp.1354-1358, 2012.
DOI : 10.1093/jac/dks079

H. Sader, M. Castanheira, R. Flamm, D. Farrell, and R. Jones, Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011, Antimicrobial Agents and Chemotherapy, vol.57, issue.4, pp.2436-2448, 1982.
DOI : 10.1128/AAC.02436-12

M. Castanheira, S. Farrell, K. Krause, R. Jones, and H. Sader, Contemporary Diversity of ??-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent ??-Lactamase Groups, Antimicrobial Agents and Chemotherapy, vol.58, issue.2, pp.833-83801896, 2014.
DOI : 10.1128/AAC.01896-13

R. Flamm, G. Stone, H. Sader, R. Jones, and W. Nichols, Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value, Journal of Chemotherapy, vol.79, issue.6, pp.333-338, 0145.
DOI : 10.1146/annurev.mi.41.100187.003041

H. Li, M. Estabrook, G. Jacoby, W. Nichols, R. Testa et al., Susceptibility of Characterized ??-Lactamase-Producing Strains Tested with Avibactam Combinations, Antimicrobial Agents and Chemotherapy, vol.59, issue.3, pp.1789-179304191, 2015.
DOI : 10.1128/AAC.04191-14

K. Papp-wallace, S. Bajaksouzian, A. Abdelhamed, A. Foster, M. Winkler et al., Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single ??-lactamases, Diagnostic Microbiology and Infectious Disease, vol.82, issue.1, pp.65-69, 2015.
DOI : 10.1016/j.diagmicrobio.2015.02.003

A. Yoshizumi, Y. Ishii, K. Aoki, R. Testa, W. Nichols et al., In??vitro susceptibility of characterized ??-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations, Journal of Infection and Chemotherapy, vol.21, issue.2, pp.148-151, 2015.
DOI : 10.1016/j.jiac.2014.08.028

W. Nichols, Permeability of Bacteria to Antibacterial Agents, Antibiotic drug discovery and development, pp.849-879, 2012.
DOI : 10.1007/978-1-4614-1400-1_26

J. Pagès, S. Peslier, W. Nichols, J. Lavigne, and T. Keating, Porins and the ceftazidime-avibactam (CAZ-AVI) susceptibility of -lactamaseproducing Enterobacteriaceae, abstr F-947, Abstr 54th Intersci Conf Antimicrob Agents Chemother, 2014.

A. Pantel, A. Boutet-dubois, H. Jean-pierre, H. Marchandin, A. Sotto et al., French regional surveillance program of carbapenemase-producing Gram-negative bacilli: results from a 2-year period, European Journal of Clinical Microbiology & Infectious Diseases, vol.12, issue.12, pp.2285-2292, 2014.
DOI : 10.1007/s10096-014-2189-5

M. Malléa, C. J. Bornet, C. Eyraud, A. Davin-regli, A. Bollet et al., Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes, Microbiology, vol.144, issue.11, pp.3003-3009, 1998.
DOI : 10.1099/00221287-144-11-3003

S. Gayet, R. Chollet, G. Molle, J. Pagès, and C. J. , Modification of Outer Membrane Protein Profile and Evidence Suggesting an Active Drug Pump in Enterobacter aerogenes Clinical Strains, Antimicrobial Agents and Chemotherapy, vol.47, issue.5, pp.1555-1559, 2003.
DOI : 10.1128/AAC.47.5.1555-1559.2003

J. Chevalier, J. Pagès, A. Eyraud, and M. Malléa, Membrane Permeability Modifications Are Involved in Antibiotic Resistance in Klebsiella pneumoniae, Biochemical and Biophysical Research Communications, vol.274, issue.2, pp.496-499, 2000.
DOI : 10.1006/bbrc.2000.3159

U. Hasdemir, C. J. Nordmann, P. Pagès, and J. , Detection and Prevalence of Active Drug Efflux Mechanism in Various Multidrug-Resistant Klebsiella pneumoniae Strains from Turkey, Journal of Clinical Microbiology, vol.42, issue.6, pp.2701-2706, 2004.
DOI : 10.1128/JCM.42.6.2701-2706.2004

V. Kuete, S. Alibert-franco, K. Eyong, B. Ngameni, G. Folefoc et al., Antibacterial activity of some natural products against bacteria expressing a multidrug-resistant phenotype, International Journal of Antimicrobial Agents, vol.37, issue.2, pp.156-161, 2011.
DOI : 10.1016/j.ijantimicag.2010.10.020
URL : https://hal.archives-ouvertes.fr/hal-00659899

L. Mamelli, S. Petit, C. J. Giglione, C. Lieutaud, A. Meinnel et al., New Antibiotic Molecules: Bypassing the Membrane Barrier of Gram Negative Bacteria Increases the Activity of Peptide Deformylase Inhibitors, PLoS ONE, vol.3, issue.7, 2009.
DOI : 10.1371/journal.pone.0006443.t005
URL : https://hal.archives-ouvertes.fr/hal-00853795

C. Bornet, N. Saint, L. Fetnaci, M. Dupont, A. Davin-régli et al., Omp35, a New Enterobacter aerogenes Porin Involved in Selective Susceptibility to Cephalosporins, Antimicrobial Agents and Chemotherapy, vol.48, issue.6, pp.2153-2158, 2004.
DOI : 10.1128/AAC.48.6.2153-2158.2004

M. Viveiros, M. Dupont, L. Rodrigues, I. Couto, A. Davin-regli et al., Antibiotic Stress, Genetic Response and Altered Permeability of E. coli, PLoS ONE, vol.41, issue.4, 2007.
DOI : 10.1371/journal.pone.0000365.t001

J. Pagès, J. Lavigne, V. Leflon-guibout, E. Marcon, F. Bert et al., Efflux Pump, the Masked Side of ??-Lactam Resistance in Klebsiella pneumoniae Clinical Isolates, PLoS ONE, vol.48, issue.9, 2009.
DOI : 10.1371/journal.pone.0004817.t007

N. Antunes, H. Frase, M. Toth, and S. Vakulenko, The Class A ??-Lactamase FTU-1 Is Native to Francisella tularensis, Antimicrobial Agents and Chemotherapy, vol.56, issue.2, pp.666-67105305, 2012.
DOI : 10.1128/AAC.05305-11

J. Berkhout, M. Melchers, A. Van-mil, W. Nichols, and J. Mouton, Checkerboard Assays, Antimicrobial Agents and Chemotherapy, vol.59, issue.2, pp.1138-114404146, 2015.
DOI : 10.1128/AAC.04146-14

M. Huband, W. Nichols, G. Stone, L. Otterson, and P. Bradford, Ceftazidime-avibactam: use of a predictor panel to evaluate and optimize avibactam concentrations for in vitro susceptibility testing, abstr P1290, Abstr 25th Eur Congr Clin Microbiol Infect Dis, p.25, 2015.

A. Asli, E. Brouillette, K. Krause, W. Nichols, and F. Malouin, Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria, Antimicrobial Agents and Chemotherapy, vol.60, issue.2, 2015.
DOI : 10.1128/AAC.02102-15

S. Vidal, J. Bredin, J. Pagès, and J. Barbe, ??-Lactam Screening by Specific Residues of the OmpF Eyelet, Journal of Medicinal Chemistry, vol.48, issue.5, pp.1395-1400, 2005.
DOI : 10.1021/jm049652e

G. Schulz, The structure of bacterial outer membrane proteins, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1565, issue.2, pp.308-317, 2002.
DOI : 10.1016/S0005-2736(02)00577-1

A. Beceiro, S. Maharjan, T. Gaulton, M. Doumith, N. Soares et al., False extended-spectrum ??-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins, Journal of Antimicrobial Chemotherapy, vol.66, issue.9, pp.2006-2010, 2011.
DOI : 10.1093/jac/dkr265

K. Mahendran, M. Kreir, H. Weingart, N. Fertig, and M. Winterhalter, Permeation of Antibiotics through Escherichia coli OmpF and OmpC Porins: Screening for Influx on a Single-Molecule Level, Journal of Biomolecular Screening, vol.15, issue.3, pp.302-307, 2010.
DOI : 10.1177/1087057109357791

. Cerexa, Ceftazidime-avibactam briefing package. NDA 206494 Division of Anti-Infective Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Advisory Committees/CommitteesMeetingMaterials/Drugs/Anti-Infective DrugsAdvisoryCommittee/UCM425458.pdf. Accessed 21, 2014.

D. Yang, Y. Guo, and Z. Zhang, Combined Porin Loss and Extended Spectrum ??-Lactamase Production is Associated with an Increasing Imipenem Minimal Inhibitory Concentration in Clinical Klebsiella??pneumoniae Strains, Current Microbiology, vol.47, issue.4, pp.366-370, 2009.
DOI : 10.1007/s00284-009-9364-4